Kilitch Drugs Financials
| KILITCH Stock | 313.80 0.30 0.1% |
Kilitch | Select Account or Indicator |
Kilitch Drugs Stock Summary
Kilitch Drugs competes with Electronics Mart, Indian Metals, Rajnandini Metal, Associated Alcohols, and Manaksia Coated. Kilitch Drugs is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE729D01010 |
| Business Address | 3739, Ujagar Industrial |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.kilitch.com |
| Phone | 91 22 6121 4100 |
You should never invest in Kilitch Drugs without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kilitch Stock, because this is throwing your money away. Analyzing the key information contained in Kilitch Drugs' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Kilitch Drugs Key Financial Ratios
Kilitch Drugs' financial ratios allow both analysts and investors to convert raw data from Kilitch Drugs' financial statements into concise, actionable information that can be used to evaluate the performance of Kilitch Drugs over time and compare it to other companies across industries.| Revenue | 1.54 B | ||||
| Gross Profit | 707.85 M | ||||
| EBITDA | 286.33 M | ||||
| Net Income | 193.54 M | ||||
| Cash And Equivalents | 1.34 M |
Kilitch Drugs Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 2.0B | 2.1B | 2.2B | 2.4B | 2.8B | 1.7B | |
| Other Current Liab | 22.3M | 15.8M | 17.7M | 16.8M | 15.1M | 14.3M | |
| Net Debt | 23.6M | 104.2M | 23.5M | 127.4M | 114.6M | 68.2M | |
| Cash | 124.5M | 100.1M | 198.5M | 189.1M | 217.5M | 228.3M | |
| Net Receivables | (522K) | 414.3M | 542.9M | 632.6M | 569.3M | 597.8M | |
| Inventory | 35.9M | 52.9M | 20.4M | 93.1M | 83.8M | 49.7M | |
| Other Current Assets | 279.3M | 20.0M | 28.8M | 43.5M | 50.0M | 47.5M | |
| Total Liab | 737.0M | 695.5M | 689.4M | 643.9M | 579.5M | 357.3M | |
| Total Current Assets | 803.6M | 1.1B | 1.3B | 1.5B | 1.7B | 916.0M | |
| Short Term Debt | 148.0M | 204.3M | 221.9M | 316.5M | 363.9M | 382.1M | |
| Common Stock | 154.3M | 154.9M | 155.8M | 160.8M | 184.9M | 150.7M | |
| Accounts Payable | 536.5M | 428.7M | 408.7M | 255.9M | 294.3M | 177.6M | |
| Retained Earnings | 518.2M | 591.8M | 696.3M | 842.3M | 968.7M | 624.5M | |
| Intangible Assets | 1.5M | 2.3M | 204.8M | 4.4M | 5.1M | 4.9M | |
| Other Liab | 3.9M | 3.8M | 2.8M | 683K | 614.7K | 584.0K | |
| Net Tangible Assets | 954.5M | 1.1B | 1.2B | 1.3B | 1.5B | 1.1B | |
| Other Assets | 17.2M | 19.7M | 19.8M | 1.0 | 0.9 | 0.86 | |
| Short Long Term Debt | 148.0M | 204.3M | 221.9M | 316.5M | 363.9M | 382.1M | |
| Good Will | 219.1M | 210.6M | 202.2M | 193.8M | 174.4M | 189.4M | |
| Net Invested Capital | 1.4B | 1.6B | 1.7B | 2.1B | 2.4B | 1.7B | |
| Net Working Capital | 70.5M | 448.3M | 575.3M | 817.8M | 940.4M | 499.5M | |
| Capital Stock | 154.3M | 154.9M | 155.8M | 160.8M | 184.9M | 171.5M |
Kilitch Drugs Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 7.5M | 12.0M | 49.2M | 60.4M | 69.4M | 72.9M | |
| Total Revenue | 685.2M | 1.1B | 1.4B | 1.5B | 1.8B | 889.7M | |
| Gross Profit | 312.2M | 488.0M | 648.4M | 620.5M | 713.5M | 749.2M | |
| Operating Income | 41.3M | 100.2M | 148.6M | 208.1M | 187.2M | 196.6M | |
| Ebit | 60.0M | 109.5M | 171.0M | 252.8M | 227.6M | 238.9M | |
| Ebitda | 79.8M | 134.1M | 206.5M | 286.3M | 257.7M | 129.9M | |
| Cost Of Revenue | 373.1M | 654.3M | 747.6M | 923.2M | 830.9M | 421.4M | |
| Income Before Tax | 51.2M | 96.1M | 120.1M | 193.5M | 174.2M | 182.9M | |
| Net Income | 36.7M | 73.7M | 104.5M | 146.0M | 131.4M | 66.0M | |
| Income Tax Expense | 13.5M | 34.0M | 37.3M | 57.8M | 66.5M | 69.8M | |
| Minority Interest | 23.5M | 11.5M | 21.7M | 10.3M | 11.8M | 15.3M | |
| Tax Provision | 13.5M | 34.0M | 37.3M | 57.8M | 66.5M | 69.8M | |
| Net Interest Income | (7.5M) | (12.0M) | (49.2M) | (59.3M) | (53.4M) | (50.7M) | |
| Interest Income | 7.5M | 12.0M | 49.2M | 4.1M | 4.7M | 4.5M |
Kilitch Drugs Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Kilitch Drugs Limited. It measures of how well Kilitch is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Kilitch Drugs brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Kilitch had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Kilitch Drugs has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 19.7M | (14.1M) | 29.6M | (19.4M) | (22.3M) | (21.2M) | |
| Change In Cash | 97.0M | (24.4M) | 133.4M | (8.8M) | (10.2M) | (9.7M) | |
| Free Cash Flow | 93.6M | (24.2M) | 23.2M | (121.2M) | (139.4M) | (146.3M) | |
| Depreciation | 19.9M | 24.7M | 35.5M | 33.5M | 30.1M | 32.6M | |
| Other Non Cash Items | 5.7M | (11.1M) | 19.0M | (40.6M) | (46.7M) | (49.0M) | |
| Capital Expenditures | 363.0M | 82.0M | 2.6M | 64.5M | 58.1M | 106.0M | |
| Net Income | 51.2M | 96.1M | 120.1M | 193.5M | 174.2M | 182.9M | |
| End Period Cash Flow | 125.0M | 100.6M | 234.0M | 189.6M | 218.1M | 229.0M | |
| Investments | (2.7M) | (69.3M) | 114.7M | (95.4M) | (85.9M) | (81.6M) | |
| Net Borrowings | 31.6M | 21.9M | 25M | 17.6M | 20.3M | 21.1M | |
| Change To Netincome | (38.7M) | 20.9M | 19.8M | 43.1M | 49.6M | 52.1M |
Kilitch Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kilitch Drugs's current stock value. Our valuation model uses many indicators to compare Kilitch Drugs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kilitch Drugs competition to find correlations between indicators driving Kilitch Drugs's intrinsic value. More Info.Kilitch Drugs Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.68 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Kilitch Drugs Limited is roughly 1.47 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kilitch Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kilitch Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Kilitch Drugs Limited Systematic Risk
Kilitch Drugs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kilitch Drugs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Kilitch Drugs Limited correlated with the market. If Beta is less than 0 Kilitch Drugs generally moves in the opposite direction as compared to the market. If Kilitch Drugs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kilitch Drugs Limited is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kilitch Drugs is generally in the same direction as the market. If Beta > 1 Kilitch Drugs moves generally in the same direction as, but more than the movement of the benchmark.
Kilitch Drugs Limited Total Assets Over Time
Kilitch Drugs Thematic Clasifications
Kilitch Drugs Limited is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Kilitch Drugs February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kilitch Drugs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kilitch Drugs Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kilitch Drugs Limited based on widely used predictive technical indicators. In general, we focus on analyzing Kilitch Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kilitch Drugs's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.2 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 15.78 | |||
| Value At Risk | (3.03) | |||
| Potential Upside | 4.68 |
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |